Blood test may spot cancer return months before scans
NCT ID NCT07426250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test that detects tumor DNA (ctDNA) can help predict cancer recurrence in 500 patients with oligometastatic cancer (cancer that has spread to only a few spots). Participants will give blood samples before and after local treatment (like surgery or radiation). Researchers will track whether ctDNA levels relate to cancer coming back or survival. The goal is to see if this test could guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could show that a simple blood test (ctDNA) helps doctors detect cancer return earlier and personalize follow-up care for patients with limited metastases.
What could go wrong
This is an observational study, not a treatment trial. It will not test a new therapy, and results may not change current practice. ctDNA detection rates vary by cancer type, so findings may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC CANCER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Oncology, Aarhus University Hospital
Aarhus N, 8200, Denmark
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact